Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors

Molecular Cancer Therapeutics

Volumn 4, Issue 5, 2005, Pages 843-854

  Azrak, Rami G ^a   Yu, Jinsheng ^b   Pendyala, Lakshmi ^a   Smith, Patrick F ^a   Cao, Shousong ^a   Li, Xia ^b   Shannon, William D ^b   Durrani, Farukh A ^a   McLeod, Howard L ^b   Rustum, Youcef M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; IRINOTECAN; METHYLSELENOCYSTEINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG TISSUE LEVEL; FEMALE; GENE EXPRESSION; HEAD AND NECK CANCER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CYSTEINE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, NUDE; ORGANOSELENIUM COMPOUNDS; PHARMACOGENETICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 20044392488     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-04-0315     Document Type: Article

References (39)

1. Ma MK, McLeod HL. Lessons learned from the irinotecan metabolic pathway. Curr Med Chem 2003;10:41-9.
2. Rivory LP. Irinotecan (CPT-11): a brief overview. Clin Exp Pharmacol Physiol 1996;23:1000-4.
3. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-91.
4. Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001;2:9-39.
5. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-49.
6. McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001;41: 101-21.
7. Lavelle F, Bissery MC, Andre S, Roquet F, Riou JF. Preclinical evaluation of CPT-11 and its active metabolite SN-38. Semin Oncol 1996;23: 11-20.
8. Rivory LP, Bowles MR, Robert J, Pond SM. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 1996;52: 1103-11.
9. Wiseman LR, Markham A. Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1996;52:606-23.
10. Satoh T, Hosokawa M, Atsumi R, Suzuki W, Hakusui H, Nagai E. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 1994;17:662-4.
11. Senter PD, Beam KS, Mixan B, Wahl AF. Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug. Bioconjug Chem 2001;12:1074-80.
12. Gupta R, Mick R, Ramirez J, et al. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 1997;15:1502-10.
13. Xu G, Zhang W, Ma MK, McLeod HL. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 2002;8:2605-11.
14. Rivory L, Riou JF, Haaz MC, et al. Identification and properties of major plasmid metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res 1996;56:3689-94.
15. Santos A, Zanetta S, Cresteil T, et al. Metabolism of Irinotecan (CPT-11) by CYP2A4 and CYP3A5 in humans. Clin Cancer Res 2000;6:2012-20.
16. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001;42:1007-16.
17. Chen CJ, Clark D, Ueda K, Pastan I, Gottesman MM, Roninson IB. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem 1990;5;265:506-14.
18. Motwani M, Sirotnak FM, She Y, Commes T, Schwartz GK. Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells. Cancer Res 2002;62:3950-5.
19. Hwang PM, Bunz F, Yu J, et al. Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat Med 2001;7:1111-7.
20. Liu G, Chen X. The ferredoxin reductase gene is regulated by the p53 family and sensitizes cells to oxidative stress-induced apoptosis. Oncogene 2002;21:7195-04.
21. Sharma HW, Narayanan R. The NF-κB transcription factor in oncogenesis [review]. Anticancer Res 1996;16:589-96.
22. Rangaswami H, Bulbule A, Kundu GC. Nuclear factor inducing kinase plays crucial role in osteopontin induced MAPK/IKK dependent nuclear factor κB-mediated promatrix metalloproteinase-9 activation. J Biol Chem 2004;279:38921-35.
23. Embree-Ku M, Venturini D, Boekelheide K. Fas is involved in the p53-dependent apoptotic response to ionizing radiation in mouse testis. Biol Reprod 2002;66:1456-61.
24. Ip C. Lessons from basic research in selenium and cancer prevention. J Nutr 1998;128:1845-54.
25. Kim T, Jung U, Cho DY, Chung AS. Se-methylselenocysteine induces apoptosis through activation in HL-60 cells. Carcinogenesis 2001;22: 559-65.
26. Yeo JK, Cha SD, Cho CH, et al. Se-methylselenocysteine induces apoptosis through caspase activation and Bax cleavage mediated by calpain SKOV-3 ovarian cancer cells. Cancer Lett 2002;182:83-92.
27. Medina D, Thompson H, Ganther H, Ip C. Se-methylselenocysteine: a new compound for chemoprevention of breast cancer. Nutr Cancer 2001; 40:12-27.
28. Thompson HJ, Wilson A, Lu J, et al. Comparison of the effects of an organic and inorganic form of selenium on a mammary carcinoma cell line. Carcinogenesis 1994;15:183-6.
29. Sinha R, Medina D. Inhibition of cdk2 kinase activity by Semethylselenocysteine in synchronized mouse mammary epithelial cells. Carcinogenesis 1997;18:1541-7.
30. Azrak RG, Cao S, Slocum HK, et al. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin Cancer Res 2004;10:1121-9.
31. Cao S, Durrani FA, Rustum YM. Selective modulation of the therapeutics efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res 2004;10:2561-9.
32. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
33. Warner DL, Burke TG. Simple and versatile high-performance liquid chromatography method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. J Chromatogr B Biomed Sci Appl 1997;691:161-71.
34. Yu J, Shannon WD, Watson MA, McLeod HL. Gene expression profiling of the irinotecan pathway in colorectal cancer. Clin Cancer Res 2005;11:2053-62.
35. Liu W, Saint DA. A new quantitative method of real time reverse transcription polymerase chain reaction assay based on simulation of polymerase chain reaction kinetics. Anal Biochem 2002;302:52-9.
36. Jansen WJ, Hulscher TM, van Ark-Otte J, Giaccone G, Pinedo HM, Boven E. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein. Br J Cancer 1998;77:359-65.
37. Chu XY, Suzuki H, Ueda K, Kato Y, Akiyama S, Sugiyama Y. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. J Pharmacol Exp Ther 1999;288:735-41.
38. Zhou RH, Kokame K, Tsukamoto Y, Yutani C, Kato H, Miyata T. Characterization of the human gene family: a newly identified member, ndrg4, is specifically expressed in brain and heart. Genomics 2001;73: 86-7.
39. Bhattacharya A, Tóth K, Mazurchuk R, et al. Lack of microvessels in well differentiated regions of human head and neck squamous cell carcinoma A253 is associated with fMR imaging detectable hypoxia, limited drug delivery and resistance to irinotecan therapy. Clin Cancer Res 2004;10:8005-17.